Not a good buy right now for an impatient trader: price action is weak (down today), momentum indicators are bearish, and there is no proprietary “must-buy” signal.
The stock is sitting right on/just below the first support zone (~1.936). That can produce bounces, but the current setup is not showing confirmation.
Options positioning is extremely call-heavy (bullish/speculative), but liquidity is thin and implied volatility is extremely elevated—this is not an “easy” entry.
Trend/Momentum: Bearish-to-neutral. MACD histogram is below zero (-0.00749) and negatively expanding, implying downside momentum is strengthening.
RSI (6): 36.763, near oversold but still technically “neutral” — suggests selling pressure is present, but not yet a clear reversal signal.
Moving averages: Converging MAs often precede a bigger move; given MACD weakness, near-term bias remains downside until price reclaims key levels.
Key levels:
Immediate support: S1 1.936 (price ~1.93 is right at this level); next support S2 1.867.
Overhead resistance/inflection: Pivot 2.046, then R1 2.157 and R2 2.226.
Practical read: A “good buy now” would ideally come after reclaiming ~2.05 (pivot) or after a clear bounce/hold above 1.94 with improving momentum—neither is evident today.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Extremely call-skewed (OI put/call 0.07) with effectively zero put volume today (volume put/call 0.0) → strongly bullish/speculative positioning.
Volatility: Implied vol (30D) ~265.71% vs historical vol ~92.67% → options are pricing very large moves; risk/reward for new long calls is generally unfavorable at these IV levels.
Activity: Today’s options volume is 12 contracts (low in absolute terms) but flagged as elevated vs its own recent baseline (today vs 30D avg ~3.24x). Open interest is ~5,714 with very call-heavy composition (calls 5,346 vs puts 368).
Takeaway: Options are signaling “upside hope,” but the extremely high IV and low absolute volume make this more speculative than confirmatory.
Technical Summary
Sell
7
Buy
3
Positive Catalysts
on 2026-03-04 (pre-market) can act as a volatility catalyst (guidance/cash runway/program updates).
Neutral/Negative Catalysts
No near-term news flow in the last week → limited fresh catalysts to reverse the current weakness immediately.
Weak tape today: -4.46% regular-session move with additional pre-market weakness (-1.98%) suggests near-term sellers are in control.
High cash burn / development-stage risk: continued losses with no revenue; dilution/financing risk is a standing overhang for small-cap biotech.
Options IV is extremely high → market is pricing significant risk; this often coincides with unstable price action.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no meaningful operating revenue; unchanged YoY).
Net income: -$56.755M, worsening ~21.77% YoY (higher loss).
EPS: -$0.35, worsening ~22.22% YoY.
Growth trend read: financial trajectory is dominated by R&D spend and losses; investment case relies on pipeline milestones rather than operating earnings.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent changes:
2026-01-06: Mizuho raised PT to $6 (from $5), reiterated Outperform, citing encouraging NMRA-511 Phase 1b signal in a pre-specified AD subset.
2025-11-17: Stifel raised PT to $3 (from $2), reiterated Hold; noted Phase 1b readout as “arguably upside-skewed” given low expectations.
Street “pros” view:
Upside optionality from clinical catalysts; improving sentiment reflected in raised targets.
If follow-on data validate earlier signals, the stock could re-rate quickly from depressed levels.
Street “cons” view:
Still early/uncertain clinical translation; low visibility on timing and magnitude of value inflection.
Ongoing losses and funding overhang typical of pre-revenue biotech.
Wall Street analysts forecast NMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMRA is 9.33 USD with a low forecast of 3 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMRA is 9.33 USD with a low forecast of 3 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
1 Sell
Moderate Buy
Current: 2.020
Low
3
Averages
9.33
High
18
Current: 2.020
Low
3
Averages
9.33
High
18
Mizuho
Outperform
maintain
$5 -> $6
AI Analysis
2026-01-06
Reason
Mizuho
Price Target
$5 -> $6
AI Analysis
2026-01-06
maintain
Outperform
Reason
Mizuho raised the firm's price target on Neumora Therapeutics to $6 from $5 and keeps an Outperform rating on the shares after the company made several announcements, highlighted by positive Phase 1b signal-seeking results for NMRA-511 in Alzheimer's disease agitation. Better results seen in a pre-specified subset of AD patients with elevated anxiety is "an encouraging finding," the analyst tells investors.
Stifel
Hold
maintain
$2 -> $3
2025-11-17
Reason
Stifel
Price Target
$2 -> $3
2025-11-17
maintain
Hold
Reason
Stifel raised the firm's price target on Neumora Therapeutics to $3 from $2 and keeps a Hold rating on the shares following Q3 earnings and hosting management at the firm's annual Healthcare Conference. NMRA-511's Phase 1b readout in AD agitation is expected to readout by year-end and expectations are low despite favorable initial tolerability data, making this catalyst "arguably upside-skewed," the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NMRA
